PTC THERAPEUTICS ($PTCT) posted quarterly earnings results for Q2 2026 on Thursday, July 30th. The company reported earnings of $0.92 per share, beating estimates of $0.41 by $0.51. The company also reported revenue of $360,520,000, beating estimates of $303,993,068 by $56,526,932.
Stock price change since market close: +3.28%
You can see Quiver Quantitative's $PTCT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
PTC THERAPEUTICS Insider Trading Activity
PTC THERAPEUTICS insiders have traded $PTCT stock on the open market 71 times in the past 6 months. Of those trades, 0 have been purchases and 71 have been sales.
Here’s a breakdown of recent trading of $PTCT stock by insiders over the last 6 months:
- NEIL GREGORY ALMSTEAD (CHIEF TECHNICAL OPS OFFICER) has made 0 purchases and 26 sales selling 166,513 shares for an estimated $13,244,388.
- MARK ELLIOTT BOULDING (EXEC. VP AND CLO) has made 0 purchases and 23 sales selling 29,531 shares for an estimated $2,233,611.
- ERIC PAUWELS (CHIEF BUSINESS OFFICER) has made 0 purchases and 3 sales selling 24,296 shares for an estimated $1,805,172.
- MATTHEW B. KLEIN (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 7 sales selling 25,455 shares for an estimated $1,801,080.
- CHRISTINE MARIE UTTER (SVP, CHIEF ACCOUNTING OFFICER) has made 0 purchases and 2 sales selling 22,180 shares for an estimated $1,660,458.
- STEPHANIE OKEY has made 0 purchases and 3 sales selling 21,500 shares for an estimated $1,463,075.
- MARY L. SMITH has made 0 purchases and 2 sales selling 15,834 shares for an estimated $1,425,060.
- LEE SCOTT GOLDEN (EVP & CHIEF MEDICAL OFFICER) has made 0 purchases and 3 sales selling 13,313 shares for an estimated $862,453.
- PIERRE GRAVIER (CHIEF FINANCIAL OFFICER) has made 0 purchases and 2 sales selling 6,486 shares for an estimated $488,268.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
PTC THERAPEUTICS Hedge Fund Activity
We have seen 180 institutional investors add shares of PTC THERAPEUTICS stock to their portfolio, and 149 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. removed 1,128,551 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $76,888,179
- TORONTO DOMINION BANK removed 1,112,252 shares (-26.9%) from their portfolio in Q1 2026, for an estimated $75,777,728
- CITADEL ADVISORS LLC removed 769,256 shares (-66.6%) from their portfolio in Q1 2026, for an estimated $52,409,411
- ARMISTICE CAPITAL, LLC removed 727,420 shares (-26.0%) from their portfolio in Q1 2026, for an estimated $49,559,124
- HOOD RIVER CAPITAL MANAGEMENT LLC added 661,484 shares (+65.9%) to their portfolio in Q1 2026, for an estimated $45,066,904
- QUBE RESEARCH & TECHNOLOGIES LTD added 513,823 shares (+inf%) to their portfolio in Q1 2026, for an estimated $35,006,760
- LOOMIS SAYLES & CO L P added 493,603 shares (+inf%) to their portfolio in Q1 2026, for an estimated $33,629,172
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
PTC THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $PTCT recently. We have seen 7 analysts offer price targets for $PTCT in the last 6 months, with a median target of $92.0.
Here are some recent targets:
- Brian Abrahams from RBC Capital set a target price of $85.0 on 07/07/2026
- Geoff Meacham from Citigroup set a target price of $108.0 on 06/09/2026
- Faisal Khurshid from Jefferies set a target price of $85.0 on 05/27/2026
- Benjamin Burnett from Wells Fargo set a target price of $95.0 on 05/08/2026
- Joseph Thome from TD Cowen set a target price of $90.0 on 05/08/2026
- Jeffrey Hung from Morgan Stanley set a target price of $92.0 on 02/23/2026
- Tazeen Ahmad from B of A Securities set a target price of $93.0 on 02/20/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
